Codexis, Inc. - CDXS STOCK NEWS

Codexis (CDXS) and Molecular Assemblies announced advancements in their partnership focused on Fully Enzymatic Synthesis™ (FES™) technology, utilizing Codexis’ engineered enzymes for enhanced DNA synthesis. The collaboration has produced a refined version of terminal deoxynucleotidyl transferase (TdT) polymerase, which improves synthesis accuracy and efficiency. A Key Customer Program will begin later this year, allowing select clients access to long, custom oligonucleotides. FES technology aims to disrupt traditional chemical methods, streamlining synthetic biology applications.

Codexis (Nasdaq:CDXS), an enzyme engineering company, announced participation in the Cowen 42nd Annual Health Care Conference set for March 7-9, 2022. Management will engage in a panel discussion titled “Synthetic Biology Enabling Discovery” on March 8 at 3:30 p.m. ET, followed by a fireside chat on March 9 at 1:30 p.m. ET. Both sessions will be webcasted and accessible in the Investor Relations section of the Codexis website for 30 and 90 days post-event. The company focuses on advancing synthetic biology through innovative enzyme solutions.

Codexis reported a record total revenue of $104.8 million for 2021, marking a 52% increase from 2020 and achieving its eighth consecutive year of revenue growth. Product revenues more than doubled to $70.7 million, driven primarily by sales to Pfizer for the COVID-19 drug PAXLOVID™. The company projects 2022 total revenues between $152 million and $158 million, reflecting anticipated continued growth. Despite increased R&D and SG&A expenses, Codexis maintains a solid cash position of $116.8 million.

Codexis (Nasdaq:CDXS) announced it will report its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call and webcast for discussing the results will be held at 4:30 p.m. ET. Participants can join the live call by dialing 877-705-2976 (domestic) or (201) 689-8798 (international). The webcast will be available for archiving for 90 days. Codexis leverages its proprietary CodeEvolver platform for novel enzyme development impacting various industries.

Codexis (NASDAQ: CDXS) announced that the FDA has granted orphan drug designation and rare pediatric disease designation for its drug candidate CDX-6512, aimed at treating homocystinuria. This enzyme therapy is in pre-IND development and is positioned as a first-in-class oral treatment. The orphan designation provides incentives such as tax credits and potential marketing exclusivity for seven years upon FDA approval. Preclinical data showcasing CDX-6512 was previously presented at the ICIEM in November 2021.

Codexis, a prominent enzyme engineering company, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference, scheduled from January 10-13, 2022. The event will take place virtually, allowing investors and interested parties to access a webcast starting January 10 at 7:00 a.m. ET. This presentation will be archived for 90 days on the company's website. Codexis utilizes its CodeEvolver® platform to enhance enzyme performance across pharmaceuticals, food, and industrial applications, showcasing its commitment to sustainable practices and health improvements.

Codexis, a prominent enzyme engineering company, announced the launch of its Codex® HiTemp Reverse Transcriptase, designed for one-step quantitative reverse transcription PCR (RT-qPCR) applications. This enzyme addresses critical challenges in viral diagnostics, including those for SARS-CoV-2. Key features include enhanced thermostability up to 70°C, improved robustness against clinical sample degradation, and a rapid turnaround time of five minutes for reverse transcription reactions. The enzyme is now available for bulk supply, supporting the ongoing demand for efficient viral RNA detection.

Codexis, Inc. (NASDAQ: CDXS) announced key advancements in biotherapeutic programs targeting homocystinuria (HCU) and maple syrup urine disease (MSUD) at the 14th International Congress of Inborn Errors of Metabolism in Sydney. CDX-6512 demonstrated up to 45% suppression of serum homocysteine in HCU mice, while a leucine decarboxylase showed similar results in MSUD models. Codexis aims to develop these gastrointestinal-stable enzymes as oral therapies, potentially improving treatment options for patients constrained by dietary restrictions. The company remains optimistic about further clinical advancements.

Codexis, a leading enzyme engineering company, announced participation in three upcoming virtual investment conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference features an on-demand fireside chat starting November 22, 2021, at 10:00 a.m. ET. The Stephens Annual Investment Conference will host its fireside chat on November 29, 2021, at 2:00 p.m. ET, followed by the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 4:45 p.m. ET. Webcasts will be available for 30 days on the company’s website.